Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis
Go back to Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis| (NASDAQ: CNTB) | Delayed: 1.36 -0.01 (0.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.37 | 52 Week High | $ | |||
| Open | $1.32 | 52 Week Low | $ | |||
| Day High | $1.40 | P/E | N/A | |||
| Day Low | $1.31 | EPS | $ | |||
| Volume | 33,937 | |||||
